Related Experiment Video
Updated: May 5, 2026
Gene Expression Profiling of Infecting Microbes Using a Digital Bar-coding Platform
Published on: January 13, 2016
Transcriptomics Insights into Targeting CK2 Complex in Cryptococcus neoformans: Implications for Large-Scale
Fadia Falah Hassan1, Mohammed Hussein Mushrif2, Mohammed F Hamdi3
1Biology department, College of education for Pure Science-Ibn Alhaitham, University of Baghdad, Baghdad, Iraq.
Background And Purpose:
Cryptococcus neoformans is a pathogenic fungus that causes fungal meningitis and other infections in immunocompromised patients. The casein kinase 2 (Ck2) complex regulates cellular processes. This study provides transcriptomics and functional insights into the Ck2 complex and other pathogenic proteins of Cryptococcus neoformans as therapeutic targets.
Materials And Methods:
The study used computational methods to explore the transcriptomic and functional aspects of the Ck2 complex and other pathogenic proteins in Cryptococcus neoformans. RNA-sequencing analysis of control and experimental cell cultures under three different conditions (cka1Δ mutant vs wild, ckaΔ, ckb1Δ, ckb2Δ [triple] mutants vs wild, and wild vs all mutants) was performed, followed by the STRING analysis of the dysregulated genes to identify the protein-protein interactions, while Cytoscape was used to identify the hub genes in all three conditions.
Results:
The RNA-sequencing analysis resulted in various dysregulated genes such as 936 (cka1Δ mutant vs wild), 1154 (triple vs wild), and 1159 (wild vs all mutants). Cellular components, molecular functions, and KEGG pathways in three conditions. The hub genes that elevated the most, Q5KFT2_CRYNJ, ARO1_CRYNJ, Q5KL19_CRYNJ, Q5KC42_CRYNJ, Q5KNI6_CRYNJ, Q5KCS1_CRYNJ, Q5KNH2_CRYNJ, Q5KA46_CRYNJ, Q5KEV1_CRYNJ, Q5KFT0_CRYNJ, Q5KAB9_CRYNJ, Q5KN73_CRYNJ, Q5KLJ6_CRYNJ, and Q5KHQ2_CRYNJ, were selected for FDA-approved drugs screening using GNINA, resulting in three potential drugs (amphotericin B, idarubicin, and candicidin) for respective proteins.
Conclusions:
The Ck2 complex in C. neoformans regulates cellular processes, including proliferation and apoptosis. Disruption of this complex affects cellular functions. This study identifies deletion mutations and pathogenic proteins, revealing top-performing drugs. Further clinical investigations are needed to confirm these findings.
Insights
This study explores the casein kinase 2 (Ck2) complex in Cryptococcus neoformans, identifying potential drug targets for treating fungal infections. RNA-sequencing and computational analyses revealed key pathogenic proteins and screened for effective FDA-approved drugs.
Area of Science:
- Mycology
- Molecular Biology
- Computational Biology
Background:
- Cryptococcus neoformans is a significant fungal pathogen causing meningitis in immunocompromised individuals.
- The casein kinase 2 (Ck2) complex plays a crucial role in regulating essential cellular processes within C. neoformans.
Purpose of the Study:
- To investigate the transcriptomic and functional roles of the Ck2 complex and other pathogenic proteins in C. neoformans.
- To identify potential therapeutic targets for C. neoformans infections.
Main Methods:
- Utilized RNA-sequencing to analyze gene expression in C. neoformans under various mutant conditions.
- Employed STRING and Cytoscape for protein-protein interaction analysis and identification of hub genes.
- Screened identified hub genes against FDA-approved drugs using GNINA.
Main Results:
- Identified significant numbers of dysregulated genes across different mutant strains (e.g., 936, 1154, 1159).
- Determined key cellular components, molecular functions, and KEGG pathways affected by gene dysregulation.
- Selected several high-ranking hub genes (e.g., Q5KFT2_CRYNJ, ARO1_CRYNJ) for drug screening.
Conclusions:
- The Ck2 complex is vital for C. neoformans proliferation and apoptosis; its disruption impacts cellular functions.
- Identified three potential drugs—amphotericin B, idarubicin, and candicidin—as promising therapeutic agents against C. neoformans proteins.
- Further clinical studies are warranted to validate these drug candidates for treating fungal infections.
